Compare GF & VRXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GF | VRXA |
|---|---|---|
| Founded | 1990 | 2021 |
| Country | Germany | Germany |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.5M | 161.2M |
| IPO Year | N/A | 2025 |
| Metric | GF | VRXA |
|---|---|---|
| Price | $9.80 | $1.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.2K | ★ 142.5K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.88 | $0.90 |
| 52 Week High | $12.49 | $4.50 |
| Indicator | GF | VRXA |
|---|---|---|
| Relative Strength Index (RSI) | 32.04 | 45.85 |
| Support Level | N/A | $0.92 |
| Resistance Level | $11.82 | $1.29 |
| Average True Range (ATR) | 0.23 | 0.10 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 4.50 | 32.57 |
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investments includes investments in different sectors such as the industrials, information technology, materials, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.